Videos

In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Lee explains study findings suggesting MetALD classification should be based on ≥ 3 cardiometabolic risk factors rather than just alcohol intake.

This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well as patients’ unmet needs.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

Laique reviews data supporting the use of metabolic surgery in patients with obesity and cirrhotic MASH.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

In this segment of January's Lungcast episode, guests discussed the Global Lung Function Initiative (GLI) network, lung function testing, and the use of race-based normal values.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

This month’s Lungcast features a discussion on pulmonary function tests and the controversial practice of using race-based normal values.

Panelists discuss how shared decision-making is essential when considering emerging treatments vs established therapies, emphasizing the importance of aligning treatment choices with patient preferences and values to enhance adherence and optimize outcomes in IgA nephropathy care.

Panelists discuss how the approval of atrasentan is expected to significantly affect the treatment landscape for IgA nephropathy by offering a novel therapeutic option that targets both proteinuria reduction and the underlying immune dysregulation associated with the disease.

In this episode, hosts explore the latest updates to the ADA Standards of Care on therapeutic innovations and their real-world impact on diabetes management.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

Joselyn Rojas-Quintero, MD, speaks about her team's current research into COPD treatment on this issue of The Respiratory Report.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

Abebaw Yohannes, MSc, PhD, speaks about his team’s pilot study designed to assess the use of duloxetine for patients with COPD and comorbid depression.

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

This summarizes the latest in our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

In this episode, hosts explore ADA's evolving guidelines championing broader access to CGM and AID systems for personalized diabetes care.

Flemming describes increasing rates of AH among adolescents and young adults, with females facing the greatest increases and worse outcomes than males.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.